B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. - Wikidata - awgldk - TriplyDB

B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis.

B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis.

http://www.wikidata.org/entity/Q33759287

about

PD-L1 expression in human cancers and its association with clinical outcomes Mesothelioma treatment: Are we on target? A review PD-L1 and Survival in Solid Tumors: A Meta-Analysis Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies Modern management of malignant pleural mesothelioma Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis.Novel systemic therapy against malignant pleural mesothelioma.Immunotherapy for malignant pleural mesothelioma: current status and future directions.Malignant pleural mesothelioma: an update on diagnosis and treatment options.Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials The impact of thymoma histotype on prognosis in a worldwide database.Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).Diffuse high intensity PD-L1 staining in thymic epithelial tumors.Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas.Effects of lung cancer cell-associated B7-H1 on T-cell proliferation in vitro and in vivo.Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer.Local and systemic therapies for malignant pleural mesothelioma.Searching for targets for the systemic therapy of mesothelioma.Evaluating the effect of immune cells on the outcome of patients with mesothelioma.Optimal Therapy of Advanced Stage Mesothelioma.Adoptive T-Cell Therapy for Solid Tumors.A catalogue of treatment and technologies for malignant pleural mesothelioma.Advances in treatment of mesothelioma.Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab.Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma.Anti-CTLA-4 therapy for malignant mesothelioma.Immunotherapy for malignant mesothelioma: Reality check.Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab.Clinical staging of malignant pleural mesothelioma: current perspectives.Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients.Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma.PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma.Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining.Advances in systemic therapy for malignant mesothelioma: future perspectives.Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial.New horizons from immunotherapy in malignant pleural mesothelioma.Spontaneous Regression of Malignant Pleural Mesothelioma in a Patient with New-Onset Inflammatory Arthropathy.Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes.

P2860

Q26738361-CA537302-7904-4842-A9B7-9F6F310CAFB3 Q26800042-045F4DFE-4E9F-49DE-A8DD-DB71CBB1556F Q28084090-AD1BD273-47BF-4228-B59C-93D6B6E51E5B Q28395597-34BD7D73-AEC6-4BF0-B1E7-D2D45A47A020 Q29248127-96D31CD5-C5CE-44FA-AF2A-4AC9E00805FF Q33644049-1E5E25CC-957F-45C7-82A6-8527D55AFF3A Q33890499-0F5BBF76-8307-4FB4-B41E-C15274C22555 Q33890551-7643ED3D-12B8-4901-B2DE-503222E747A6 Q34513958-C4FEFEF8-A9F2-44B8-B927-5F0CFA09768E Q34622818-157CD35D-8AF9-40DF-B64E-0885FB1897E4 Q35054167-72A9D349-616E-42AB-AF33-76D53CF0C8A6 Q35182037-E32CCCA3-B0BF-473E-97E6-A96CA2CD1EA7 Q36483074-804410B0-391C-4D9B-9CFB-1A12989BD534 Q36962460-B1BEDC67-70DE-4FF4-B980-AEA65F45A719 Q37032948-DDB23A4A-4563-416F-83D8-20709C9A86E6 Q37281262-D3B27AE5-E4E5-4DB0-A489-8977EA23FC88 Q38255347-DE1A83C9-02F3-428F-B888-71561B386636 Q38365768-7FCD9238-71D5-4160-BD3B-64A9A8EA1604 Q38619743-3E40EEFF-9032-43E0-B5A8-5596F98EFF42 Q38662242-2F563BBD-6C7D-4EAA-9F12-FE06AEDA0B22 Q38754498-0DF1CFAD-BB5F-4659-A7AC-01B87E9210ED Q38760623-1450628D-388C-4F88-A997-2F077AFDFCB1 Q38800916-F16D5D92-2DE9-4B34-BF8A-ECE79F052FE2 Q38895586-60C7EA27-D6E1-4435-9C86-F92B2F1C987A Q38961442-88C4423B-8ADB-4E35-8412-41B8AD466B0C Q39148274-459E5367-78C0-4B01-AB9D-A9DE23B83618 Q39351008-EF2E4C54-DBA2-44BB-B62B-9C72FD2A9479 Q39470931-DE1F81AC-A7D7-44E7-B0E7-A9C33A7049E5 Q41522440-1CD8D636-9051-4457-819E-42FEE842228D Q46115026-52233EEF-89B2-43CF-9543-2A7F32281F61 Q47393402-23661A06-0AF3-4CE3-8EEF-F919D50C4BC8 Q47654312-91CF0AEC-013F-448A-B529-1CF8EA4C00E9 Q47784813-338EEBE1-DA92-4F00-881C-A7FC14DA27E6 Q47912434-65CCDD1F-DF7C-4142-93BF-79CFBB00B1A5 Q47948817-1085FCF4-E5F9-45BD-B0E4-9A6AA5B73FCE Q51416101-3AB9CA0F-2DDB-4702-B7C3-B2B4F0B465E3 Q52579899-47F81C34-E7BD-4106-AB5E-FE450AE94B51 Q52672888-C1E5E9E0-8BC4-4838-9C82-2B83458DAFEC Q52990918-9EA63217-B1FF-401E-9F78-7EF4E1CCF708 Q54748161-6D722B80-525F-42A9-8C33-4D4FC1D8FD7A

P2860

B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis.

http://www.wikidata.org/entity/Q33759287

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

B7-H1 expression in malignant ...... histology and poor prognosis.

@ast

B7-H1 expression in malignant ...... histology and poor prognosis.

@en

type

label

B7-H1 expression in malignant ...... histology and poor prognosis.

@ast

B7-H1 expression in malignant ...... histology and poor prognosis.

@en

prefLabel

B7-H1 expression in malignant ...... histology and poor prognosis.

@ast

B7-H1 expression in malignant ...... histology and poor prognosis.

@en

P1433

Q33759287-D740DE96-A27D-46FD-9DE3-59E703FC0C1A

P1476

Q33759287-66619967-DB36-4532-82B9-9A9C1D1903F0

P2093

Q33759287-0B896254-A15D-439C-A138-057609BA3C2D

Q33759287-0F082377-A834-4F12-9250-E33A53A20642

Q33759287-109CBBA2-A169-45DF-8D2F-2D19990BEE9D

Q33759287-7C4FC396-3082-47BB-BF62-F221C6CEE651

Q33759287-9D0AE106-E771-4E5B-A185-5EE1A5598832

Q33759287-A80EB38E-FCE2-418B-9474-DC92DF3AA149

Q33759287-C7D6409C-6C96-42F6-B2A1-13B81FBDD3FA

P2860

Q33759287-0FC8D9BF-00D4-4C6E-9C56-3638AB9A1586

Q33759287-0FFA3F1E-38C0-4E06-9BB7-5EFC21F55A64

Q33759287-1C4E9E18-DA33-4BA6-981D-93BC4E97E5E5

Q33759287-1EB05268-6ADE-4C9D-8311-3A51AB6BE599

Q33759287-229B5EA7-E757-484D-A5CF-44F802B89218

Q33759287-28BCA2D6-7704-44DF-889F-558924FB03C1

Q33759287-3289907F-BF2B-446F-86E9-92950C924950

Q33759287-3BE97717-FB66-4A26-839D-1E8579865492

Q33759287-467F628E-39EC-40F3-A0AF-40EE4A2CBA76

Q33759287-5787F50E-C7CE-49B9-BE07-FB7D85F0927B

P304

Q33759287-D85384EE-BCC4-4E82-851B-5E302949EEE5

P31

Q33759287-5BCB7C03-0E96-4771-AC4D-7D2E03539AFD

P356

Q33759287-28BE1A77-D75F-49D1-A625-C6AE710196DC

P433

Q33759287-3C188B70-5D08-42CC-A400-AF0C58B563A7

P478

Q33759287-AC38FDBA-E1BC-4747-9681-6B20AE9D04DD

P50

Q33759287-DF505AD8-9FCB-4028-B59E-FAA2DDB6EE5B

P577

Q33759287-5C2E87F1-0A2B-45BE-88E5-F6769439C5A0

P698

Q33759287-B9937CA4-A5D1-442B-A56D-1B0904946202

P932

Q33759287-4D3F3EDA-3D13-4939-BB78-8F45CD8A51A4

P356

JTO.0000000000000177

P1433

Journal of Thoracic Oncology

P1476

B7-H1 expression in malignant ...... histology and poor prognosis.

@en

P2093

Anja C Roden

http://www.w3.org/2001/XMLSchema#string

Christopher J Krco

http://www.w3.org/2001/XMLSchema#string

Eugene D Kwon

http://www.w3.org/2001/XMLSchema#string

Haidong Dong

http://www.w3.org/2001/XMLSchema#string

Susan M Harrington

http://www.w3.org/2001/XMLSchema#string

Tobias Peikert

http://www.w3.org/2001/XMLSchema#string

Yuri M Sheinin

http://www.w3.org/2001/XMLSchema#string

P2860

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

Nivolumab plus ipilimumab in advanced melanoma.

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

P304

1036-1040

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/JTO.0000000000000177

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Aaron Mansfield

P577

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24926549

http://www.w3.org/2001/XMLSchema#string

P932

4058651

http://www.w3.org/2001/XMLSchema#string